Evaluating the combined efficacy of Telisotuzumab Vedotin and artificial intelligence in the treatment of non-squamous non-small cell lung cancer: a narrative review focusing on pharmaceutical and technical insights
{{output}}
Background: Non-squamous Non-small Cell Lung Cancer (NSCLC) is among the most common lung cancers that are therapy-resistant. Telisotuzumab Vedotin (Teliso-V), an antibody-drug conjugate (ADC), targets mesenchymal-epithelial tran... ...
